Tag:
Neurogen
Latest Headlines
Latest Headlines
Ligand strikes deal to buy struggling Neurogen
Three months after slashing half of its workforce and shelving research work, Neurogen has agreed to be bought out by Ligand Pharmaceuticals for $11 million in stock and the chance to earn millions
Neurogen suspends enrollment, cuts staff
Psychiatric and neurological drug developer Neurogen says it has suspended the enrollment of additional patients in its ongoing Phase II studies for Parkinson's disease and Restless Legs Syndrome, as
Neurogen restructures, sells assets
As part of its ongoing efforts to restructure and consolidate operations, Neurogen today announced it will be selling some of its non-core assets for $9 million. Four of its five buildings--including
SPOTLIGHT: Neurogen cuts jobs (again)
Facing a delay of clinical trials for its lead therapy, Neurogen slashed 45 more jobs and announced plans to focus its development programs. The developer also raised $30.6 million in a private
Neurogen cuts 70 jobs in restructuring
Neurogen is slashing 70 jobs in a restructuring that will focus company assets around its clinical programs. The drug developer is focused on insomnia, Parkinson's disease, restless legs syndrome and
C&L: Stem Cell agency chooses Trounson
Alan Trounson, the director of the Monash Immunology and Stem Cell Laboratories, has been named president of California's stem-cell research institute. Acceleron Pharma has named John L. Knopf,
ALSO NOTED: BDSI gains $30M milestone; Medicines Company files NDA; Neurogen names CEO; and much more...
> BioDelivery Sciences has pocketed a $30 million milestone payment from Meda as part of their licensing agreement for the commercialization of BEMA Fentanyl, a new pain patch for cancer
